XT
ATOS icon

XTX Topco’s Atossa Therapeutics ATOS Stock Holding History

XTX Topco’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,284
Closed -$99.9K – 3829
2025
Q4 		$99.9K Buy
11,284
+9,627
+581% +$122K ﹤0.01% 2640
2025
Q3 		$21.5K Buy
1,657
+821
+98% +$10.1K ﹤0.01% 2317
2025
Q2 		$10.4K Buy
+836
New +$9.99K ﹤0.01% 2230
2025
Q1 		– Sell
-5,278
Closed -$74.8K – 2402
2024
Q4 		$74.8K Buy
5,278
+1,970
+60% +$38.5K 0.01% 1824
2024
Q3 		$75.4K Buy
3,308
+1,664
+101% +$33.6K 0.01% 1645
2024
Q2 		$29.4K Buy
+1,644
New +$36.4K ﹤0.01% 1572
2024
Q1 		– Sell
-5,691
Closed -$75.1K – 1829
2023
Q4 		$75.1K Sell
5,691
-5,471
-49% -$59K 0.02% 1166
2023
Q3 		$123K Buy
11,162
+8,536
+325% +$124K 0.02% 1153
2023
Q2 		$49.6K Buy
+2,626
New +$31.8K 0.01% 1237
2022
Q1 		– Sell
-1,152
Closed -$28K – 671
2021
Q4 		$28K Buy
+1,152
New +$42.2K 0.02% 608
2021
Q2 		– Sell
-1,359
Closed -$43K – 802
2021
Q1 		$43K Buy
+1,359
New +$49.7K 0.02% 632

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco's ATOS Position: Q1 2026 in Review

XTX Topco sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 11,284 shares — an estimated $99.9K sold.

XTX Topco first reported a position in ATOS in Q1 2021 and held it in 11 quarters. The position peaked at $123K in Q3 2023. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • XTX Topco reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 11,284 Atossa Therapeutics shares in Q1 2026, an estimated $99.9K.
  • XTX Topco first reported a position in Atossa Therapeutics in Q1 2021 and held it in 11 quarters.
  • XTX Topco's Atossa Therapeutics position peaked at $123K in Q3 2023.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.